

METHODS IN MOLECULAR BIOLOGY™

Series Editor
John M. Walker
School of Life Sciences
University of Hertfordshire
Hatfield, Hertfordshire, AL10 9AB, UK

For further volumes:
<http://www.springer.com/series/7651>

Antibody-Drug Conjugates

Edited by

Laurent Ducry

Lonza Ltd, Visp, Switzerland

 **Humana Press**

Editor

Laurent Ducry
Lonza Ltd
Visp, Switzerland

ISSN 1064-3745 ISSN 1940-6029 (electronic)
ISBN 978-1-62703-540-8 ISBN 978-1-62703-541-5 (eBook)
DOI 10.1007/978-1-62703-541-5
Springer New York Heidelberg Dordrecht London

Library of Congress Control Number: 2013943693

© Springer Science+Business Media, LLC 2013

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Humana Press is a brand of Springer
Springer is part of Springer Science+Business Media (www.springer.com)

Preface

Antibody–drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. The FDA approval of Adcetris[®] (brentuximab vedotin) in 2011 and Kadcyla[®] (trastuzumab emtansine or T-DM1) in 2013 has validated the idea of making “armed” antibodies, attracting a lot of attention into this field. ADC technology has been an active area of research in recent years, resulting in a number of ADCs in development for various tumor types. The number of immunoconjugates or ADCs undergoing clinical trial will thus further increase, possibly replacing some of the existing naked monoclonal antibodies, and becoming the next generation of anticancer biotherapeutics.

Although the ADC concept is quite simple, successfully designing and developing such a “smart bomb” is a complex task. Despite a tremendous increase in our understanding in recent years, a lot of work is necessary in order to identify a suitable target; properly design the mAb, the linker, and the payload; as well as conjugate them in a reproducible and scalable fashion.

The success of the current conjugation technologies has been achieved thanks to the development of new methodologies. The aim of this book is to provide detailed protocols for many of the key ADC techniques necessary for working in the field. Each method is described by an author who has regularly used the technique in his or her laboratory. In addition, several review chapters are included to summarize the current knowledge and results in the ADC area. These should make this book useful to readers with no previous ADC experience as well as those already working in the field. It is my hope that this publication will further drive ADC development and thus help towards improving cancer treatments of the future.

Visp, Switzerland

Laurent Ducry

Contents

<i>Preface</i>	<i>v</i>
<i>Contributors</i>	<i>ix</i>
1 Antibody–Drug Conjugate (ADC) Clinical Pipeline: A Review.....	1
<i>Ingrid Sassoon and Véronique Blanc</i>	
2 Antibody–Drug Conjugate Target Selection: Critical Factors	29
<i>Neil H. Bander</i>	
3 Selecting an Optimal Antibody for Antibody–Drug Conjugate Therapy: Internalization and Intracellular Localization	41
<i>Jay Harper, Shenlan Mao, Patrick Strout, and Adeela Kamal</i>	
4 Antibody–Drug Conjugate Payloads	51
<i>Jan Anderl, Heinz Faulstich, Torsten Hechler, and Michael Kulke</i>	
5 Linker Technologies for Antibody–Drug Conjugates	71
<i>Birte Nolting</i>	
6 In Vivo Testing of Drug-Linker Stability	101
<i>Pierre-Yves Abecassis and Céline Amara</i>	
7 Pharmacokinetics and ADME Characterizations of Antibody–Drug Conjugates	117
<i>Kedan Lin, Jay Tibbitts, and Ben-Quan Shen</i>	
8 Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment.....	133
<i>Miriam I. Hensgen and Bernhard Stump</i>	
9 Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting	145
<i>James E. Stefano, Michelle Busch, Lihui Hou, Anna Park, and Diego A. Gianolio</i>	
10 Protocols for Lysine Conjugation	173
<i>Marie-Priscille Brun and Laurence Gauzy-Lazo</i>	
11 Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers.....	189
<i>Sunil Bhakta, Helga Raab, and Jagath R. Junutula</i>	
12 Enzymatic Antibody Modification by Bacterial Transglutaminase.....	205
<i>Patrick Dennler, Roger Schibli, and Eliane Fischer</i>	
13 Formulation Development of Antibody–Drug Conjugates	217
<i>William J. Galush and Aditya A. Wakankar</i>	
14 Conjugation Process Development and Scale-Up	235
<i>Bernhard Stump and Jessica Steinmann</i>	
15 Methods for Conjugating Antibodies to Nanocarriers	249
<i>Anil Wagh and Benedict Law</i>	
16 Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy	267
<i>Yan Chen</i>	

17	Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High-Performance Liquid Chromatography	275
	<i>Jun Ouyang</i>	
18	Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS	285
	<i>Louissette Basa</i>	
19	Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF	295
	<i>Joyce Lin and Alexandru C. Lazar</i>	
20	Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody–Drug Conjugates (ADCs)	303
	<i>Weibing Ding</i>	
	<i>Index</i>	313

Contributors

PIERRE-YVES ABECASSIS • *DSAR (Disposition, Safety & Animal Research), Sanofi, Vitry-sur-Seine, France*

CÉLINE AMARA • *DSAR (Disposition, Safety & Animal Research), Sanofi, Vitry-sur-Seine, France*

JAN ANDERL • *Heidelberg Pharma GmbH, Ladenburg, Germany*

NEIL H. BANDER • *Weill-Cornell Medical College, Cornell University, New York, NY, USA*

LOUISETTE BASA • *Protein Analytical Chemistry, Genentech Inc., South San Francisco, CA, USA*

SUNIL BHAKTA • *Genentech Inc., South San Francisco, CA, USA*

VÉRONIQUE BLANC • *Sanofi Oncology, Vitry-sur-Seine, France*

MARIE-PRISCILLE BRUN • *Natural Product and Protein Chemistry, Sanofi, Vitry-sur-Seine, France*

MICHELLE BUSCH • *Transitional Research, Genzyme, a Sanofi Company, Framingham, MA, USA*

YAN CHEN • *Protein Analytical Chemistry, Genentech Inc., South San Francisco, CA, USA*

PATRICK DENNLER • *Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, Switzerland*

WEIBING DING • *SLS Global Technical Support, Pall Corporation, Port Washington, NY, USA*

HEINZ FAULSTICH • *Heidelberg Pharma GmbH, Ladenburg, Germany*

ELIANE FISCHER • *Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, Switzerland*

WILLIAM J. GALUSH • *Early Stage Pharmaceutical Development, Genentech Inc., South San Francisco, CA, USA*

LAURENCE GAUZY-LAZO • *Natural Product and Protein Chemistry, Sanofi, Vitry-sur-Seine, France*

DIEGO A. GIANOLIO • *Drugs and Biomaterials R&D, Genzyme, a Sanofi Company, Cambridge, MA, USA*

JAY HARPER • *Oncology Research, MedImmune Inc., Gaithersburg, MD, USA*

TORSTEN HECHLER • *Heidelberg Pharma GmbH, Ladenburg, Germany*

MIRIAM I. HENSGEN • *Bioconjugates R&D, Lonza Ltd, Visp, Switzerland*

LIHUI HOU • *Transitional Research, Genzyme, a Sanofi Company, Framingham, MA, USA*

JAGATH R. JUNUTULA • *Genentech Inc., South San Francisco, CA, USA*

ADEELA KAMAL • *Oncology Research, MedImmune Inc., Gaithersburg, MD, USA*

MICHAEL KULKE • *Heidelberg Pharma GmbH, Ladenburg, Germany*

BENEDICT LAW • *Department of Pharmaceutical Sciences, College of Pharmacy, Nursing and Allied Sciences, North Dakota State University, Fargo, ND, USA*

ALEXANDRU C. LAZAR • *Analytical & Pharmaceutical Sciences, ImmunoGen, Inc., Waltham, MA, USA*

JOYCE LIN • *Analytical & Pharmaceutical Sciences, ImmunoGen, Inc., Waltham, MA, USA*

KEDAN LIN • *Early Development Pharmacokinetics and Pharmacodynamics, Genentech Inc., South San Francisco, CA, USA*

SHENLAN MAO • *Oncology Research, MedImmune Inc., Gaithersburg, MD, USA*

BIRTE NOLTING • *Biotherapeutics Research and Development, Pfizer, Pearl River, NY, USA*

JUN OUYANG • *Pharma Technical Regulatory, Genentech Inc., South San Francisco, CA, USA*

ANNA PARK • *Transitional Research, Genzyme, a Sanofi Company, Framingham, MA, USA*

HELGA RAAB • *Genentech Inc., South San Francisco, CA, USA*

INGRID SASSOON • *Sanofi Oncology, Vitry-sur-Seine, France*

ROGER SCHIBLI • *Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, Switzerland*

BEN-QUAN SHEN • *Early Development Pharmacokinetics and Pharmacodynamics, Genentech Inc., South San Francisco, CA, USA*

JAMES E. STEFANO • *Transitional Research, Genzyme, a Sanofi Company, Framingham, MA, USA*

JESSICA STEINMANN • *Bioconjugates R&D, Lonza Ltd, Visp, Switzerland*

PATRICK STROUT • *Oncology Research, MedImmune Inc., Gaithersburg, MD, USA*

BERNHARD STUMP • *Bioconjugates R&D, Lonza Ltd, Visp, Switzerland*

JAY TIBBITTS • *Drug Metabolism and Pharmacokinetics, UCB Celltech Slough, Berkshire, UK*

ANIL WAGH • *Department of Pharmaceutical Sciences, College of Pharmacy, Nursing and Allied Sciences, North Dakota State University, Fargo, ND, USA*

ADITYA A. WAKANKAR • *Late Stage Pharmaceutical Development, Genentech Inc., South San Francisco, CA, USA*